The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The Role of MicroRNAs in Hepatocellular Carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most common cancers, leading to the second cancer-related death in the global. Although the treatment of HCC has greatly improved over the past few decades, the survival rate of patients is still quite low. Thus, it is urgent to explore new therapies, especially seek for more accurate biomarkers for early diagnosis, treatment and prognosis in HCC. MicroRNAs (miRNAs), small noncoding RNAs, are pivotal participants and regulators in the development and progression of HCC. Great progress has been made in the studies of miRNAs in HCC. The key regulatory mechanisms of miRNAs include proliferation, apoptosis, invasion, metastasis, epithelial-mesenchymal transition (EMT), angiogenesis, drug resistance and autophagy in HCC. And exosomal miRNAs also play important roles in proliferation, invasion, metastasis, and drug resistance in HCC by regulating gene expression in the target cells. In addition, some miRNAs, including exosomal miRNAs, can be as potential diagnostic and prediction markers in HCC. This review summarizes the latest researches development of miRNAs in HCC in recent years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“It has been proved that miRNAs play crucial roles in multiple biological processes by regulating gene expression, and the abnormal expression of miRNAs are related to numerous cancers and many other diseases [19].”
BackgroundFang, T., Lv, H., Lv, G., Li, T., Wang, C., Han, Q., Yu, L., Su, B., Guo, L., Huang, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02583-0 · Cited by 995
Cited by
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J.-C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 575
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Analysis of the role of the Hippo pathway in cancer
Han, Y. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1869-4 · Cited by 287
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
Yang, Y., Zhang, W., Wang, X., Yang, J., Cui, Y., Song, H., Li, W., Li, W., Wu, L., Du, Y., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.998666 · Cited by 16
Metadata
- Authors
- Xu, X., Tao, Y., Shan, L., Chen, R., Jiang, H., Qian, Z., Cai, F., Ma, L., & Yu, Y.
- Venue
- Journal of Cancer
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 9
- Issue
- 19
- Pages
- 3557-3569
- ISSN
- 1837-9664 (ISSN-L)
- OpenAlex
- W2892196248
- Cited by
- 175
- References
- 5
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.